FX 06

Drug Profile

FX 06

Alternative Names: FX 06-RI; FX 06-SS; FX06; FX06 HS; FX06 MRI; Peptide Bβ15-42

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator FIBREX Medical
  • Developer F4 Pharma; FIBREX Medical
  • Class Anti-inflammatories; Peptides
  • Mechanism of Action Cadherin 5 modulators; Fibrin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Capillary leak syndrome; Delayed graft function; Shock; Systemic inflammatory response syndrome
  • Discontinued Reperfusion injury

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Capillary-leak-syndrome in Austria (IV)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Delayed-graft-function(Prevention) in Austria (IV)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Shock in Austria (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top